Established in 2012, Medigen Vaccine Biologics Corp (MVC) is a subsidiary of Medigen Biotechnology Corp (www.medigen.com.tw), Taipei, Taiwan. MVC develops vaccines and biosimilars for important unmet medical needs. Our focus is to deliver affordable medicines for developing countries and with a particular focus on SE Asia. We aim to become one of the leading pharmaceutical companies for Taiwan and global communities. Humanity, innovation, and quality are MVC core values. We integrate biomedical technologies to improve human health so that every person, from infants to seniors, has a chance to be free from infectious diseases. Our most advanced products are MVC-1901 and MVC-EVA71. MVC-1901 is a spike-protein-based subunit vaccine for COVID-19. Based on a very large phase 2 trial powered to assess safety and efficacy by immunobridging, the vaccine has EUA status in Taiwan. Phase 3 trials for full approval are in progress. MVC-EVC71A is an inactivated whole virus-based vaccine for enteroviral disease in children between 2 months and 12 years of age. The vaccine has recently completed a phase 3 trial and is currently in regulatory review for commercial licensing.
-
Industry
-
Biotechnology Research
-
Company size
-
51-200 employees
-
Headquarters
-
Taipei
-
Type
-
Public Company
-
Founded
-
2012
-
Specialties
-
Biotechnology and Vaccines
